There was insufficient material from the primary tumour to enable a follow-up NGS analysis for comparison with the metastases, but a later confirmatory targeted NGS analysis of the liver metastasis showed the same KRAS mutation and also a TP53 mutation (c.743G > A). This evidence concerns the gene KRAS and neoplasm.